商务合作
动脉网APP
可切换为仅中文
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY. GE HealthCare’s management team will present its growth strategies, technology portfolio, and vision for its businesses via a live webcast and will be accessible at https://investor.gehealthcare.com/news-events/events.
芝加哥--(商业新闻短讯)--GE HealthCare(纳斯达克:GEHC)是精准医疗创新的领导者,将于2024年11月21日(星期四)在纽约举办投资者日。GE HealthCare的管理团队将通过网络直播展示其增长战略、技术组合和业务愿景,并可访问https://investor.gehealthcare.com/news-events/events.
More information, including registration details, will be available as the date draws closer..
随着日期的临近,将提供更多信息,包括注册详细信息。。
About GE HealthCare Technologies Inc.
关于GE HealthCare Technologies Inc。
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.
GE HealthCare是全球领先的医疗技术、药物诊断和数字解决方案创新者,致力于提供集成的解决方案、服务和数据分析,使医院更高效、临床医生更有效、治疗更精确,患者更健康、更快乐。
Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring.
GE HealthCare为患者和提供者服务了125多年,正在推进个性化、互联化和富有同情心的护理,同时简化患者跨越护理路径的旅程。我们的成像、超声、患者护理解决方案和药物诊断业务共同帮助改善患者护理,从诊断到治疗再到监测。
We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits..
我们是一家价值196亿美元的企业,拥有约51000名员工,致力于创造一个医疗保健无限的世界。。
Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
在LinkedIn、X(前Twitter)和Insights上关注我们的最新消息,或访问我们的网站https://www.gehealthcare.com/了解更多信息。
最近内容 查看更多
研究性Seladelpar在原发性胆汁性胆管炎的肝病进展和瘙痒减少方面表现出显著改善
12 小时前
Mirum Pharmaceuticals的LIVMARLI数据在ESPGHAN年会上展示
13 小时前
Oak Hill Bio和Chiesi Group宣布第一名患者参与恢复的2b期临床研究,评估OHB-607预防支气管肺发育不良,支气管肺发育异常是早产儿慢性肺病的最常见原因
1 天前
相关公司查看更多
GE Healthcare
数字化解决方案提供商
产业链接查看更多
所属赛道